LH
Labcorp Holdings Inc.
September 22, 2026 · pre-market
- Rarity
- 1.81
- Peak move
- −6.11%
- Float cap
- $26.3B
Labcorp Holdings Inc. provides innovative and comprehensive laboratory services, including routine and specialty diagnostics and drug development laboratory capabilities. It serves physicians, hospitals, health systems, pharmaceutical and biotechnology companies, researchers, patients, and other healthcare providers worldwide. Through its Diagnostics and Biopharma Laboratory Services segments, it supports clinical testing, precision medicine, and drug development.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
5 events · 0 from SEC or newswire · 0 timed with the moveinstitutional_flowNykredit A/S disclosed acquiring a new stake of 23,785 Labcorp Holdings (LH) shares during the second quarter, valued at approximately $6.66 million.
- Key event
analyst_ratingBaird reiterated its Buy rating on Labcorp Holdings (LH).
- Key event
analyst_ratingTruist Financial raised its price target on Labcorp Holdings (LH) to $365 from $350 while maintaining a Buy rating, in a report dated Sept 21, 2026.
- Key event
financial_regulatoryCMS released preliminary CY2027 Clinical Laboratory Fee Schedule rates on Sept 21, 2026, cutting Medicare lab payments by up to 15% annually through 2029 and ~16% below 2026 levels across 1,171 of 1,528 codes, estimated to save ~$1 billion yearly, affecting Labcorp's routine-testing revenue from Jan 1, 2027.
guidance_changeLabcorp issued an update on its FY 2026 earnings guidance on Friday, providing EPS guidance of $18.10-$18.55 versus the $18.34 consensus, and revenue guidance of $14.7-$14.8 billion versus the $14.7 billion consensus.